Navigation Links
Scripps Research team sheds new light on how blood clots form
Date:6/13/2011

Scripps Research Institute scientists have discovered new elements of the blood clot-formation process. The findings could lead to better drugs for preventing heart attacks and other clot-related conditions.

The work, which was published by the Journal of Clinical Investigation in an advance, online edition June 13, 2011, helps to establish a new model of clot formation.

According to the old model, an injury to the wall of blood vessels causes smooth muscle cells to expose a clot-organizing protein called tissue factor. "In the emerging new model, tissue factor exists on the surfaces of these smooth muscle cells, as well as on circulating immune cells, but in an inactive state," said Scripps Research Professor Wolfram Ruf. "In this study, we've shown that cell-surface receptor P2X7, which was known to promote inflammation when stimulated, also plays a major role in the clot-forming process by activating tissue factor."

An Intriguing Target

To better understand clot formation, Ruf and his colleagues performed a set of experiments on cultured mouse cells and transgenic mouse models. The team's investigation began with the P2X7 receptor, because of its known role in the inflammatory response that can lead to excessive clotting in sepsis, a severe illness in which the bloodstream is overwhelmed by bacteria.

Normally, when cells are damaged, they release large quantities of energy-storage molecules known as adenosine triphosphate (ATP). Previous research had hinted that when this freed ATP encounters passing immune cells, it serves as a damage signal, stimulating the immune cells' P2X7 receptors and causing the release of "microparticles" exposing the clot-promoting tissue factor. The new study showed that ATP can affect P2X7 receptors on both immune cells and smooth muscle cells.

To confirm the significance of the P2X7 receptor in the clot-forming process, the team bred transgenic mice that lacked functional P2X7 receptors, and found that these P2X7-knockout mice failed to form stable arterial blood clots when the vessel wall was exposed to a clot-inducing substance. Importantly, these mice did not suffer from uncontrollable bleeding. "This suggests that clot-preventing drugs targeting the P2X7 pathway might not have unacceptable side effects," said Ruf.

In the cell experiments, the team found that the cascade of molecular events following P2X7 stimulation alters the activity of a thiol-targeting enzyme known as protein disulfide isomerase (PDI), which Ruf's previous studies had implicated as a possible activator of tissue factor. In the new study, the scientists demonstrated the importance of PDI in this process by showing that they could block clot formation in normal mice with anti-PDI antibodies.

Targeting the top of the clot-formation pathway by blocking the P2X7 receptor might have even broader beneficial effects, since the activation of this receptor occurs in a number of inflammatory disorders.

"Cardiovascular disease and heart attacks are caused by chronic inflammation as well as clot formation," said Ruf, "so possibly P2X7 is a major explanation for the link between inflammation and thrombosis, as well as a good target for preventing these conditions."


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research scientists awarded $2.2 million to develop treatment for multi-drug addiction
2. Scripps Research scientist wins $1.9 million grant to study malaria
3. Scripps Research scientists find way to block stress-related cell death
4. Scripps Research scientists find key mechanism in transition to alcohol dependence
5. Scripps Research scientists create new genetic model of premature aging diseases
6. Scripps Research scientists identify mechanism of long-term memory
7. Scripps Research scientists uncover new DNA role in modifying gene function
8. Scripps Research scientists find dual switch regulates fat formation
9. Common chaperone protein found to work in surprising way, say Scripps Research scientists
10. Dr. Daniel Von Hoff presented with top genomics award from Scripps
11. Scripps Research team discovers new details about medically important protein family
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, a ... heart failure and type 2 diabetes, announced that ... novel adeno-associated virus (AAV) vector developed in the ... Ph.D., at Stanford University. The company plans to ... gene therapy product pipeline. "Early ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 2016  Anaconda BioMed S.L., a pre-clinical stage medical ... generation neuro-thrombectomy system for the treatment of Acute Ischemic ... MD to join its Scientific Advisory Board (SAB). The ... of scientific and clinical experts to Anaconda BioMed S.L., ... BRAIN ® to its clinical phase. The SAB ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...
Breaking Biology Technology: